Views

WHITE PAPER – Are there only 10 commercial strategies in pharma?

WHITE PAPER – Are there only 10 commercial  strategies in pharma?

It goes without saying that strategic planning is an important determinant of the success of any asset, brand or portfolio. Done well it can set direction, shape performance, provide focus for the organisation and enable thoughtful allocation of resources. But add in the reality of project management, team alignment, coordination across geographies, review meetings, slide development, rehearsals and often the sheer length of the process, and it can sometimes start to feel like an obstacle to implementation or getting on with the day job.
It’s useful to remind ourselves however, that on one level strategy isn’t that complex, or at least there aren’t that many options. I’m going to argue that there are 10 commercial strategies in pharma. I invite readers to dispute this. Whatever the final number I suspect it will be finite and manageable…

Complete the information below to download your free copy of the White Paper

For further information about our range of services

Contact Us

Share this

Related Articles

Sonar – your ‘finger on the pulse’ in the digital space
18 November 2021
Sonar – your ‘finger on the pulse’ in the digital space

Introducing Sonar – a new syndicated offer from Cello Health

Cello Health Announces New Syndicated Research Program
12 November 2021
Cello Health Announces New Syndicated Research Program

Cello Health has developed a suite of syndicated offerings tailored to support your strategic objectives at key stages in the product lifecycle. Our customizable group of reports will provide regular actionable insights from market landscape maps based on social media data, as well as ongoing tracking of HCP preferences and channel behavior.

The US Forecaster’s Check List for Japan: A World of Difference
24 September 2021
The US Forecaster’s Check List for Japan: A World of Difference

The US Forecaster’s Check List for Japan: A World of Difference

Expanding the valuation of a biopharmaceutical asset to Japan requires a new mindset in nearly every input of forecasting, with many pitfalls. Doug Willson, Senior Vice President, Cello Health Advantage and Tiffany Ahlers, Chief Commercial Officer, Mycovia Pharmaceuticals Inc., share a checklist to improve the rigor and validity of product forecasts for Japan.

Unmet Needs Analysis: Cancer Patients and Caregivers
24 September 2021
Unmet Needs Analysis: Cancer Patients and Caregivers

Using organic and unfiltered social media data, Cello Health is proud to share with you the first in a series of reports aimed at centralizing and amplifying the authentic patient experience.

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us